Alivus Life Sciences Quarterly Results for Trading Insights
In 2026, Alivus Life Sciences (ALIVUS) reported revenue ₹2,664 Cr and net profit ₹603 Cr. Analyse ALIVUS FII DII holdings to track promoter, FII and institutional holdings.
ALIVUS Quarterly Results — Revenue, Profit & EPS Highlights
Alivus Life Sciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View ALIVUS yearly price range for the annual high/low range and current price position.
- Revenue of ₹2,612 Cr in March 2026 (+0.0% vs March 2026, +7.9% vs March 2025)
- Net Profit of ₹565 Cr in March 2026 (+0.0% vs March 2026, +16.3% vs March 2025)
- EBITDA of ₹858 Cr in March 2026 (+0.0% vs March 2026)
- Operating Margin of 31.0% in March 2026 (+0.0pp vs March 2026)
- Earnings Per Share of ₹45.99 in March 2026 (+0.0% vs March 2026)
Alivus Life Sciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ALIVUS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2026 | March 2025 | March 2024 | March 2023 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,664 | 2,612 | 2,421 | 2,295 | 2,190 | 2.0% | - |
| Net Profit (₹ Cr) | 603 | 565 | 486 | 471 | 467 | - | - |
| EBITDA (₹ Cr) | 885 | 858 | 717 | 686 | 671 | - | - |
| EPS (₹) | 49.10 | 45.99 | 39.63 | 38.43 | 38.11 | - | - |
| Operating Margin (%) | 31.0% | 31.0% | 29.0% | 30.0% | 30.0% | - | - |
ALIVUS Share Price Trend — 1-Year Movement Across Quarterly Results
Alivus Life Sciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Alivus Life Sciences screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ALIVUS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Alivus Life Sciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹455,633.71 Cr | 1861.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 164.7 |
|
Divis Laboratories
Mar 2026 |
₹247,283.98 Cr | 9438.5 | 2,986 | 751 | -5.0% | - | 25.2% | 333.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4930.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 428.3 |
|
Zydus Life Science
Mar 2026 |
₹116,411.21 Cr | 1117.8 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.4 |
|
Cipla
Mar 2026 |
₹110,117.40 Cr | 1373.3 | 6,612 | 543 | -9.3% | - | 8.2% | 199.9 |
All amounts in ₹ Crores